

SEP 28 1998

Section 3

**Coamatic® Plasmin Inhibitor - 510(k) SUMMARY
(Summary of Safety and Effectiveness)**

Submitted by:

Carol Marble
Senior Regulatory Affairs Specialist
Instrumentation Laboratory Company
113 Hartwell Avenue
Lexington, MA 02173
Phone: (781) 861-4467
Fax: (781)-861-4464

Contact Persons:

Carol Marble
Phone: (781) 861-4467

Summary Prepared:

May 21, 1998

Name of the device:

Coamatic® Plasmin Inhibitor

Classification name(s):

864.7290 Factor Deficiency Test Class II
81GGP Test, Qualitative and Quantitative Factor Deficient

Identification of predicate device(s):

K833890 Coatest® Antiplasmin

Description of the device/intended use(s):

Coamatic® Plasmin Inhibitor is an *in vitro* diagnostic test for the quantitative determination of plasmin inhibitor activity in human citrated plasma using microplate, test tube and automated methods. Plasmin inhibitor, the major fast-acting inhibitor of the fibrinolytic system, also known as α_2 -antiplasmin, is an important regulator of the fibrinolytic system. Congenital deficiencies are associated with haemorrhagic problems. Decreased levels of plasmin inhibitor are observed in liver diseases and DIC. Increased levels have been reported during post-operative episodes.

Statement of How the Technological Characteristics of the Device Compare to the Predicate device:

Coamatic® Plasmin Inhibitor uses the same test principle as the predicate Coatest® Antiplasmin and is substantially equivalent in performance, intended use, and safety and effectiveness.

Summary of Performance Data:

In method comparison studies comparing the new Coamatic® Plasmin Inhibitor to the predicate Coatest® Antiplasmin, the correlation (r) on an ACL 300 (n=61) was 0.95, on a Cobas Mira (n=43) was 0.97, on an MLA Electra (n=43) was 0.97, and using the test tube (n=32) and microplate (n=54) methods was 0.96 and 0.94, respectively.

Within run precision assessed over multiple runs gave a CV of 5.9% (at a mean plasmin inhibitor concentration of 44.8%) and 2.7% (at a mean plasmin inhibitor concentration of 99.3%).



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

SEP 28 1998

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Carol Marble
Regulatory Affairs Manager
Instrumentation Laboratory Company
113 Hartwell Avenue
Lexington, Massachusetts 02173

Re: K981817/S1
Trade Name: Coamatic® Plasmin Inhibitor
Regulatory Class: II
Product Code: GGP
Dated: September 8, 1998
Received: September 9, 1998

Dear Ms. Marble:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

